Background: APOE polymorphism is believed to confer susceptibility to coronary
A polipoprotein E (apo E) plays a significant role in the receptor-mediated clearance of plasma lipo proteins, and thereby influences their circulating concentrations and distribution to various organs and tissues. The human APOE gene is located on chromo some 19 and is polymorphic,1 with three common alleles coding for the three major isoforms (*E2, *E3, *E4) and six possible genotypes. It is currently believed that the specific APOE genotype confers susceptibility to disorders such as dyslipidaemias, Alzheimer's disease and coronary heart dis ease (CHD). It may also be associated with longevity.
The frequency of each APOE isoform varies dramati cally with geographical region, race and ethnicity and the association between APOE polymorphism and disease is not always consistent.1-3 Most of the information to date has been from Western populations. It is therefore important to produce and/or update locally relevant data for other regions and races; there is little to date from the Arabian Gulf region. We therefore aimed to investigate, in this preliminary study, the pattern of APOE polymorphism in a Gulf Arab population, and ascertain to what extent a specific APOE allelic pattern could predict circulating blood lipid levels in a healthy population and in patients being investigated and treated for dyslipidaemia.
Subjects and Methods
Fasting blood samples were collected from two groups of Kuwaiti Arab subjects who were recruited into the study after informed voluntary consent and relevant ethical com mittee approval. The first group consisted of healthy blood donors (n=106, 100 males, 6 females, aged 40.5±4.7 years) presenting at the Central Blood Bank in Kuwait. All were in good general health with no evidence of chronic disease or use of medication for chronic disease. The second group consisted of patients with combined hyperlipidaemia (CH) (n=4l, 22 males, 19 females, aged 42.3±3.5 years, weight 78.2±14.5 kg, and body mass index, 25.4±4.8 kg/m2, fasting serum cholesterol>5.2 mmol/L and triglycerides >2.3 mmol/L),4 referred for investigation and manage ment at the Lipid Clinic at Mubarak A1 Kabeer Hospital, Jabriya, Kuwait. None of the subjects had diabetes or any other chronic disease requiring continuous medication. Additionally, none of these patients had commenced lipid lowering treatment, although they might have attempted lifestyle modifications (including increased physical exer cise) with varying levels of commitment. As is typical of the Kuwaiti population, about 50% of the male subjects in both groups smoked regularly. None of the women in either group admitted to cigarette smoking. For religious and cultural reasons, alcohol intake is strictly forbidden in the Emirate. The blood samples were analyzed for serum total cho lesterol (TC), triglycerides (TG), and direct HD L by rou tine autoanalyzer techniques (Beckman LX-20, BeckmanCoulter, USA). LDL concentrations were calculated using the Friedewald formula where TG levels were <4.5 mmol/L.5 The intra-and inter-assay coefficient of variations for these analyses were always less than 2.5%. The serum levels of apolipoprotein A1 and B were measured by nephelometry (Beckman Array, Beckman-Coulter, USA) with quality con trol material referable to the IFCC Reference Preparations. 6 The intra-and inter-assay coefficient of variations for apoli poprotein analyses were always less than 3.5%.
For APOE genotyping, genomic DNA was extracted from peripheral blood by the salting out technique and the common APOE genotypes determined by Hhal restric tion enzyme (New England BioLabs, MA, USA) digestion of the amplified specific PCR product in a DNA thermal cycler (GeneAmp 9700 PCR System, Applied Biosystems, CA, USA) according to well validated methods. 7 The results are expressed as means±SD as appropriate. Analysis of covariance and 2-tailed student t tests were used to explore differences between mean values across the three APOE alleles and five genotypes identified in the popula tion, as appropriate. Chi-square tests were used to compare differences in frequencies. TG levels were log-transformed prior to analyses to guarantee normality. Analysis of vari ance with interaction terms for APOE with age, gender, BMI and cigarette smoking did not indicate any statisti cally significant interactions. These tests were performed by computer using SPSS software. A P value <0.05 was considered significant.
Results
In the group of healthy blood donors there were 212 APOE alleles. The allelic frequencies were 5.7% (12/212) for *E2, 85.4% (181/212) for *E3, and 9.0% (19/212) for *E4 (Table 1 ). *E3*E3 was also the most frequent genotype, occurring in about 74% of subjects. There were no sig nificant differences in TC, HDL, LDL, apo A1 and apo B levels between the three alleles and the five genotypes iden tifiable in the blood donor population (Table 1 ). There was a tendency towards higher TG levels with APO*E2 but the difference in TG levels did not reach statistical significance in comparison with the other groups. The lipid levels in the two subjects homozygous for APO*E2 and one with genotype *E2*E4 could not be compared with values for the other groups because of the small subject numbers.
When the APOE pattern was evaluated in 41 Kuwaiti patients with combined hyperlipidemia, only two alleles, *E3 (88%) and *E4 (12%) could be identified (Table 2) . This is essentially similar to the pattern in the healthy blood donors (Table 1) . O f interest was the absence of allele *E2 and the homozygous AP0*E2 genotype. At least in this population, which even though limited in numbers was probably repre sentative of the CH population in our lipid clinic,8 there were no significant differences in lipid and lipoprotein profiles relative to specific APOE genotypes in the subjects ( Table 2 ). The single patient homozygous for *E4 did not have particu larly high lipid and lipoprotein levels, as predicted.
Discussion
APOE polymorphism has been implicated in such diseases as Alzheimer's disease and premature C H D .1,2 APO*E4 is a known genetic risk factor for CH D and Alzheimer's dis ease; *E2 is associated with longevity and a tendency toward low levels of LDL and apo B, while homozygosity for *E2 predisposes to Frederickson's type III hyperlipoproteinaemia and associated premature and accelerated atherosclerosis.1,2 However, relationships between biochemical risk factors and genetic markers differ between populations and there is a relative paucity of information on APOE from the Arabian Gulf region. In this preliminary study, we have assessed fre quencies of APOE alleles and their relationships with blood lipid and lipoprotein levels in healthy Kuwaiti blood donors and patients with combined hyperlipidaemia.
The frequencies for the *E3, *E2 and *E4 alleles were 85%, 6% and 9%, respectively, in the blood donor popula tion. These values are similar to the frequencies reported from China, Saudi Arabia and in whites.2,3,9 In African populations, however, the frequency of APO*E3 is lower (about 65%) and that of *E4 (by about 25%) ,2,10,11 A high APO*E4 frequency is also seen in indigenous populations such as the aborigines of Malaysia and Australia, Papuans, native Americans and Lapps, and is thought to indicate a 'thrifty' allele.10 In keeping with observations from Saudi Arabia, South Asians and some African populations,2,9'11 the Kuwaiti subjects studied here did not show any par ticularly strong links between APOE and lipid and apolipoprotein levels.
This preliminary study has also shown that the APOE genotype distribution in patients with combined dyslipidaemia did not differ significantly from the pattern in the blood donors. We expected that homozygous AP0*E2 would be over-represented in these patients because of its association with type III dyslipidaemia that typically pres ents with increased serum TC and TG levels.12 This was apparently not so in this study. However the relationship between APO*E2 and dyslipidaemia is controversial-it is not always consistent, and when present and expressed in heart disease, it is often in association with diabetes, obesity and/or hypothyroidism.12 None of the patients in the study was diabetic nor had evidence of thyroid disease.
In the blood donor population there was a non-signifi cant trend towards higher TG values with APO*E2. The prediction however is that APO *E2 and *E4 would be as sociated with lower and higher lipid levels respectively.12 O ur observations in this study belie that expectation. A limitation of this study may have been the small subject numbers, particularly of patients with CH. However, these subjects, to a large extent, reflect our patient population, and indeed, our observations conform with those reported in even smaller subject numbers from other non-white populations.3,9 This data is preliminary and further studies are currently ongoing in much larger groups of subjects with varying dyslipidaemias and also in patients with C H D .
We conclude that APOE genotypes in a healthy Kuwaiti population demonstrate a frequency pattern similar to that described in whites, Chinese and South Asians. The pat tern seen in a smaller group of patients with combined hy perlipidaemia is not much different. O ur data suggest that links between specific APOE type and circulating blood lipids and lipoproteins are not consistent or strong.
